{
    "Trade/Device Name(s)": [
        "ADVIA\u00ae IMS cPSA Control"
    ],
    "Submitter Information": "Bayer Healthcare LLC",
    "510(k) Number": "K061137",
    "Predicate Device Reference 510(k) Number(s)": [
        "K033379"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JJY"
    ],
    "Summary Letter Date": "July 6, 2006",
    "Summary Letter Received Date": "April 25, 2006",
    "Submission Date": "April 17, 2006",
    "Regulation Number(s)": [
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Quality Control Material (Assayed and Unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "complexed PSA (cPSA)"
    ],
    "Specimen Type(s)": [
        "Serum"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ADVIA\u00ae IMS",
        "Bayer Immuno1\u00ae systems"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for ADVIA\u00ae IMS cPSA Control, an assayed quality control material for complexed PSA assays",
    "Indications for Use Summary": "For in vitro diagnostic use to monitor the precision and accuracy of assayed, quantitative complexed PSA assays on the ADVIA\u00ae IMS and Bayer Immuno1\u00ae systems",
    "fda_folder": "Clinical Chemistry"
}